Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease.

[1]  P. Stehr-Green,et al.  Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. , 2009, International journal of epidemiology.

[2]  S. Ram,et al.  Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera , 2008, Infection and Immunity.

[3]  Peter B Gilbert,et al.  A framework for assessing immunological correlates of protection in vaccine trials. , 2007, The Journal of infectious diseases.

[4]  R. Arnold,et al.  A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. , 2007, American journal of epidemiology.

[5]  K. Rasanathan,et al.  Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to Preteens , 2007, Clinical and Vaccine Immunology.

[6]  I. Aaberge,et al.  Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. , 2007, Vaccine.

[7]  D. Kelly,et al.  Effectiveness analyses may underestimate protection of infants after group C meningococcal immunization. , 2006, The Journal of infectious diseases.

[8]  H. Keyserling,et al.  Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. , 2005, Archives of pediatrics & adolescent medicine.

[9]  D. Granoff,et al.  Naturally-acquired immunity to Neisseria meningitidis group A. , 2005, Vaccine.

[10]  Elizabeth Miller,et al.  Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction , 2004, The Lancet.

[11]  A. Bax,et al.  Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies , 1985, The Journal of experimental medicine.

[12]  N. Andrews,et al.  Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in England , 2003, Clinical Diagnostic Laboratory Immunology.

[13]  David Goldblatt,et al.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. , 2003, Vaccine.

[14]  N. Andrews,et al.  Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the pre-vaccination era. , 2003, Vaccine.

[15]  E. Rosenqvist,et al.  Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. , 2003, Vaccine.

[16]  E. Miller,et al.  Impact of meningococcal C conjugate vaccine in the UK. , 2002, Journal of medical microbiology.

[17]  M. Ramsay,et al.  Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. , 2001, Vaccine.

[18]  D. DeMets,et al.  Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. , 2001, Controlled clinical trials.

[19]  W. Blackwelder,et al.  Importance of Complement Source in Measuring Meningococcal Bactericidal Titers , 2001, Clinical Diagnostic Laboratory Immunology.

[20]  N. Andrews,et al.  Serological Basis for Use of Meningococcal Serogroup C Conjugate Vaccines in the United Kingdom: Reevaluation of Correlates of Protection , 2001, Infection and Immunity.

[21]  A. Pollard,et al.  Development of natural immunity to Neisseria meningitidis. , 2001, Vaccine.

[22]  Oleg O. Bilukha,et al.  Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). , 2000, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[23]  K. Jolley,et al.  Lack of immunity in university students before an outbreak of serogroup C meningococcal infection. , 2000, The Journal of infectious diseases.

[24]  D. Stephens.  Uncloaking the meningococcus: dynamics of carriage and disease , 1999, The Lancet.

[25]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[26]  J. Boslego,et al.  Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. , 1995, Vaccine.

[27]  C. Sacchi,et al.  Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy , 1994, Infection and immunity.

[28]  C. Sacchi,et al.  Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil , 1992, The Lancet.

[29]  Frasch Ce.  Production and control of Neisseria meningitidis vaccines. , 1990 .

[30]  C. Frasch.  Production and control of Neisseria meningitidis vaccines. , 1990, Advances in biotechnological processes.

[31]  A. Bax,et al.  Escherichia coli K51 and K93 capsular polysaccharides are crossreactive with the group A capsular polysaccharide of Neisseria meningitidis. Immunochemical, biological, and epidemiological studies. , 1985 .

[32]  C. Frasch,et al.  Protection against group B meningococcal disease: evaluation of serotype 2 protein vaccines in a mouse bacteremia model , 1979, Infection and immunity.

[33]  C. Frasch,et al.  Protection against group B meningococcal disease. III. Immunogenicity of serotype 2 vaccines and specificity of protection in a guinea pig model , 1978, The Journal of experimental medicine.

[34]  P. Vella,et al.  Clinical and Laboratory Investigations of Monovalent and Combined Meningococcal Polysaccharide Vaccines, Groups A and C , 1976, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[35]  J. Robbins,et al.  Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide , 1976, Infection and immunity.

[36]  M. Artenstein,et al.  Prevention of meningococcal disease by group C polysaccharide vaccine. , 1970, The New England journal of medicine.

[37]  M. Artenstein,et al.  Human immunity to the meningococcus. II. Development of natural immunity. , 1969 .

[38]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS I. THE ROLE OF HUMORAL ANTIBODIES , 1969 .

[39]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS IV. IMMUNOGENICITY OF GROUP A AND GROUP C MENINGOCOCCAL POLYSACCHARIDES IN HUMAN VOLUNTEERS , 1969 .

[40]  M. Artenstein,et al.  HUMAN IMMUNITY TO THE MENINGOCOCCUS : III. PREPARATION AND IMMUNOCHEMICAL PROPERTIES OF THE GROUP A, GROUP B, AND GROUP C MENINGOCOCCAL POLYSACCHARIDES , 1969 .

[41]  S. Flexner.  THE RESULTS OF THE SERUM TREATMENT IN THIRTEEN HUNDRED CASES OF EPIDEMIC MENINGITIS , 1913, The Journal of experimental medicine.